Article Text

PDF

FRI0085 Anti-beta-2- glycoprotein i antibodies in systemic lupus erythematosus patients
  1. AG Borodin,
  2. EL Nassonov,
  3. AA Baranov,
  4. NG Klukvina
  1. Department of Therapy, Medical Academy, Yaroslavl, Russia, Yaroslavl, Russia

Abstract

Methods Anticardiolipin antibodies (aCL) react with negatively charged phospholipids, which may often be complexed with a protein cofactor such as beta-2-glycoprotein I.

Results To obtain information about the prevalence and levels of IgG anti-â2-GPI, IgG- and IgM-aCL in systemic lupus erythematosus (SLE) patients (pts) these antibodies were measured, by an enzyme linked immunosorbent assay, in sera from 147 pts with SLE (70 men and 77 women). The results were compared with 20 healthy subjects. Anti-â2-GPI were found positive (more than 3s.d. above the mean in normal controls) in 15 females (19,4%), 14 males (20%) in pts with SLE compared to 1 person (5%) in normal controls. 48,3% of pts with anti-â2-GPI had the history of thrombosis, compared with 11,02% of pts without anti-â2-GPI (p < 0,001). 35,7% of females with anti-â2-GPI had the history of fetal loss, in comparison with 6,56% of anti-â2-GPI negative pts.

APS was diagnosed in 16 (69,56%) anti-â2-GPI (+)-aCL(+) pts (n = 23) and in 15 (37,5%) anti-â2-GPI (-)-aCL(+) pts (n = 40) (p < 0,01). Anti-â2-GPI(+)-aCL(+) pts had a history of thrombosis more frequently (n = 14, 60,86%) than anti-â2-GPI (+)-aCL(-) (n = 6) (n = 0, 0%, p < 0,002).

Our data show that the presence of anti-â2-GPI simultaneously with aCL is strong associated with APS in SLE.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.